Michael Dworkin, MD
Radiation Oncology · Santa Cruz, CANPI 1922505924
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,100 of the $6,028 with a category attached, or 84.6%. MIM Software Inc. accounts for 84.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $5,125 and has fallen 95.5% since, to $231 in 2025.
Across 30 payments — averaging $200.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MIM Software Inc.$5K
- Boston Scientific$276
- Pfizer$141
- Johnson & Johnson$131
- Regeneron Healthcare Solutions, Inc.$102
- Sumitomo Pharma America, Inc.$101
- plus $177 from 5 others
What the payments were for
- Consulting fees$5,10085%
- Food & beverage$92815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MIM Software Inc. | 1 | $5,100 |
| Boston Scientific | 2 | $276 |
| Pfizer | 7 | $141 |
| Johnson & Johnson | 5 | $131 |
| Regeneron Healthcare Solutions, Inc. | 4 | $102 |
| Sumitomo Pharma America, Inc. | 4 | $101 |
| Novartis | 2 | $55 |
| Coherus Oncology, Inc. | 2 | $53 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| AbbVie | 1 | $25 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,028 in reported general payments places this provider in the 85th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 27 | $72,513 |
| Tamsulosin Hcl | 40 | $440 |
| Triamcinolone Acetonide | 17 | $337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $101 | $72,51327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 627 radiation oncology providers in California.
Other radiation oncology in Santa Cruz
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
- Jyoti MayadevSan Diego$170K
- Percy LeeIrvine$125K
- Felix FengSan Francisco$99K
- Hyun KimDuarte$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.